H.C. Wainwright analyst Swayampakul Ramakanth lowered the firm’s price target on ALX Oncology to $30 from $65 and keeps a Buy rating on the shares. The analyst updated the model to reflect reported financials.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ALXO:
- ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones
- ALX Oncology announces first patient dosed in ASPEN-07 study
- ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer